Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells

Clinical Cancer Research

Volumn 18, Issue 2, 2012, Pages 417-431

  Dietrich, Sascha ^a   Krämer, Oliver H ^c   Hahn, Esther ^a   Schäfer, Claudia ^c   Giese, Thomas ^a   Hess, Michael ^a   Tretter, Theresa ^a   Rieger, Michael ^a   Hüllein, Jennifer ^b   Zenz, Thorsten ^a,b   Ho, Anthony D ^a   Dreger, Peter ^a   Luft, Thomas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; DIHYDROOROTATE DEHYDROGENASE; DRUG METABOLITE; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; JANUS KINASE; LEFLUNOMIDE; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P53; STAT PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; TERIFLUNOMIDE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR SIGNALING; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CD40 LIGAND; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROXYBUTYRATES; INTERLEUKIN-4; ISOXAZOLES; JANUS KINASES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 84855987240     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1049     Document Type: Article

References (55)

1. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6. (Pubitemid 32064784)
2. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, et al. Longterm results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-80.
3. Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009;115:2824-36.
4. Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F. How I treat refractory CLL. Blood 2006;107:1276-83. (Pubitemid 43242359)
5. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial. Lancet 2010;376:1164-74.
6. Stilgenbauer S, Zenz T, Winkler D, Buhler A, Schlenk RF, Groner S, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009;27:3994-4001.
7. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094-100. (Pubitemid 351213387)
8. Dreger P, Döhner H, Ritgen M, Bottcher S, Busch R, Dietrich S, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010;116:2438-47.
9. Zenz T, Mertens D, Kuppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37-50.
10. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114:3367-75.
11. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40- ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;106:995-1004. (Pubitemid 29463014)
12. Hallaert DY, Jaspers A, van Noesel CJ, van Oers MH, Kater AP, Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 2008;112:5141-9.
13. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009;114:4441-50.
14. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells proect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-63.
15. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115:755-64. (Pubitemid 40322252)
16. Gine E, Martinez A, Villamor N, Lopez-Guillermo A, Camos M, Martinez D, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 2010;95:1526-33.
17. Schmid C, Isaacson PG. Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 1994;24:445-51. (Pubitemid 24192314)
18. Tretter T, Schuler M, Schneller F, Brass U, Esswein M, Aman MJ, et al. Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro. Cell Immunol 1998;189:41-50. (Pubitemid 28489599)
19. Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F, et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998;92: 990-5. (Pubitemid 28355483)
20. Werneburg BG, Zoog SJ, Dang TT, Kehry MR, Crute JJ. Molecular characterization of CD40 signaling intermediates. J Biol Chem 2001;276:43334-42.
21. Wagner AH, Guldenzoph B, Lienenluke B, Hecker M. CD154/CD40- mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction. Arterioscler Thromb Vasc Biol 2004;24:715-20. (Pubitemid 38451609)
22. Danese S, Scaldaferri F, Papa A, Pola R, Gasbarrini A, Sgambato A, et al. CD40L-positive platelets induce CD40L expression de novo in endothelial cells: adding a loop to microvascular inflammation. Arterioscler Thromb Vasc Biol 2004;24:e162.
23. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009;229:152-72.
24. Hanissian SH, Geha RS. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity 1997;6:379-87. (Pubitemid 27208193)
25. Kater AP, Evers LM, Remmerswaal EB, Jaspers A, Oosterwijk MF, van Lier RA, et al. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 2004;127:404-15. (Pubitemid 39536592)
26. Conzelmann M, Wagner AH, Hildebrandt A, Rodionova E, Hess M, Zota A, et al. IFN-gamma activated JAK1 shifts CD40-induced cytokine profiles in human antigen-presenting cells toward high IL-12p70 and low IL-10 production. Biochem Pharmacol 2010;80:2074-86.
27. Douglas RS, Capocasale RJ, Lamb RJ, Nowell PC, Moore JS. Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta. Blood 1997;89:941-7. (Pubitemid 27121287)
28. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999;17:701-38. (Pubitemid 29241138)
29. Wurster AL, Rodgers VL, White MF, Rothstein TL, Grusby MJ. Interleukin- 4-mediated protection of primary B cells from apoptosis through Stat6-dependent up-regulation of Bcl-xL. J Biol Chem 2002;277:27169-75. (Pubitemid 34951732)
30. Steele AJ, Prentice AG, Cwynarski K, Hoffbrand AV, Hart SM, Lowdell MW, et al. The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood 2010;116:4569-77.
31. Siemasko K, Chong AS, Jack HM, Gong H, Williams JW, Finnegan A. Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 1998;160:1581-8. (Pubitemid 28106441)
32. Gonzalez-Alvaro I, Ortiz AM, Dominguez-Jimenez C, Aragon-Bodi A, Diaz Sanchez B, Sanchez-Madrid F. Inhibition of tumour necrosis factor and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann Rheum Dis 2009;68:1644-50.
33. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol 1999;162:2095-102. (Pubitemid 29288830)
34. Sawamukai N, Saito K, Yamaoka K, Nakayamada S, Ra C, Tanaka Y. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells. J Immunol 2007;179:6479-84.
35. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000;59:841-9.
36. van Roon EN, Jansen TL, van de Laar MA, Janssen M, Yska JP, Keuper R, et al. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:569-74. (Pubitemid 40469086)
37. Luft T, Maraskovsky E, Schnurr M, Knebel K, Kirsch M, Gorner M, et al. Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells. Blood 2004;104:1066-74. (Pubitemid 39038027)
38. Krämer OH, Baus D, Knauer SK, Stein S, Jäger E, Stauber RH, et al. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev 2006;20:473-85. (Pubitemid 43244401)
39. Schneider G, Henrich A, Greiner G, Wolf V, Lovas A, Wieczorek M, et al. Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene 29:2795-806.
40. Willimott S, Baou M, Naresh K, Wagner SD. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. Br J Haematol 2007;138:721-32. (Pubitemid 47313210)
41. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute- Working Group 1996 guidelines. Blood 2008;111:5446-56.
42. Luqman M, Klabunde S, Lin K, Georgakis GV, Cherukuri A, Holash J, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008;112:711-20.
43. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777-83.
44. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000;96:2917-24.
45. Luft T, Rodionova E, Maraskovsky E, Kirsch M, Hess M, Buchholtz C, et al. Adaptive functional differentiation of dendritic cells: integrating the network of extra- and intracellular signals. Blood 2006;107:4763-9. (Pubitemid 43882627)
46. Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Nacheva EP, et al. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood 2008;112:3827-34.
47. Speidel D. Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol 20:14-24.
48. Grad JM, Zeng XR, Boise LH. Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Curr Opin Oncol 2000;12:543-9. (Pubitemid 32039653)
49. Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T. The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia 2008;22:635-8. (Pubitemid 351386736)
50. Baumann P, Mandl-Weber S, Volkl A, Adam C, Bumeder I, Oduncu F, et al. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 2009;8:366-75.
51. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008;112:3807-17.
52. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009;113:4403-13.
53. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010;21:11-9.
54. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008;111:4681-9.
55. Elder RT, Xu X, Williams JW, Gong H, Finnegan A, Chong AS. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997;159:22-7. (Pubitemid 127493680)